How a better understanding of behavioral economics (BE) can improve the quality of structured data and bring new insights to the underwriting process in China.
How diets can affect health over time, especially for people with known pre-existing conditions, and to what extent diet might be considered during underwriting.
Insurers facing outdated technology, legacy processes, and the industry-wide retirement of experienced underwriters are taking a thorough look at how underwriting works within their businesses. RGA's Dave Rengachary offers a new vision for how RGA can help insurers thrive in the new underwriting ecosystem.
Dr. Achim Regenauer discusses how far we are along the road to having multi-cancer early detection tests – essentially powerful liquid biopsies – in the clinical setting. It appears that this is much closer than previously assumed, and that these tests will complement, rather than replace, current detection options.
What does COVID-19 do to lungs? RGA's Hilary Henly explores the permanent and irreversible lung damage caused by the disease, and shares different factors insurers should consider.
Could the pandemic weight-gain observations simply be an extension of the trends already occurring?
The rapid development of liquid biopsy technology, along with its potential for multiple clinical applications, has garnered significant excitement. RGA explores the challenges and concerns, as well as the opportunities ahead.
For the United States as a whole, and life insurers in particular, 2021 was a year marked by higher mortality as the COVID-19 pandemic entered a third year. The Centers for Disease Control and Prevention reported deaths up across many categories, higher even than 2020.